RxDoctor Payments Data

Brian Moraes, DO

Internal Medicine · Boca Raton, FLNPI 1417908823

Payments from drug & device makers

$27,720in general payments, 2019–2025

Across 843 payments — averaging $32.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Bayer$3K
  • Novo Nordisk$3K
  • AbbVie$3K
  • Lilly USA, LLC$2K
  • Boehringer Ingelheim$2K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$1,8407%
  • Food & beverage$25,86993%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,720 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$182,404
Medicare patients
365
Services billed
2,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$62,557
MounjaroTirzepatide36$35,998
JardianceEmpagliflozin23$29,807
EliquisApixaban30$27,340
FarxigaDapagliflozin Propanediol13$18,194
KerendiaFinerenone11$17,800
Breo ElliptaFluticasone/Vilanterol11$6,799
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,128
SynthroidLevothyroxine Sodium25$2,985
Rosuvastatin Calcium108$1,640
Np ThyroidThyroid,pork21$1,411
ProgesteroneProgesterone, Micronized62$1,315
Valsartan36$1,209
Ezetimibe35$1,105
Nebivolol Hcl11$1,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,073$62,55752 claims
Lilly USA, LLCMounjaro$1,771$35,99836 claims
Boehringer IngelheimJardiance$1,664$29,80723 claims
PfizerEliquis$537$27,34030 claims
AstraZenecaFarxiga$3,807$18,19413 claims
BayerKerendia$3,186$17,80011 claims
GSKBreo Ellipta, Shingrix$834$11,92734 claims
AbbVieSynthroid$2,812$2,98525 claims
Acella Pharmaceuticals, LLCNp Thyroid$50$1,41121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →